Jan Johansson group
Protein biochemistry for medical applications
Three major research lines are pursued; one concerns the BRICHOS domain for treatment of protein aggregation diseases, another line concerns development of synthetic surfactant for treatment of lung diseases and the third line focuses on molecular biology of spider silk proteins. Current activities include elucidation of the BRICHOS mechanism of action using a combination of structural biology, fibrillation kinetics, structure-function analyses, BRICHOS treatment of Alzheimer knock-in mouse models, a clinical trial of the first synthetic surfactant based on designed analogues of surfactant proteins SP-B and SP-C, studies of new surfactant protein analogues, and structure-function analyses of recombinant spider silk proteins.
A molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers.
Nat. Struct. Mol. Biol. 2015 Mar;22(3):207-213
Efficient protein production inspired by how spiders make silk.
Nat Commun 2017 05;8():15504
Bri2 BRICHOS client specificity and chaperone activity are governed by assembly state.
Nat Commun 2017 12;8(1):2081
BRICHOS domain of Bri2 inhibits islet amyloid polypeptide (IAPP) fibril formation and toxicity in human beta cells.
Proc. Natl. Acad. Sci. U.S.A. 2018 03;115(12):E2752-E2761
A spidroin-derived solubility tag enables controlled aggregation of a designed amyloid protein.
FEBS J. 2018 May;285(10):1873-1885
Department of Neurobiology, Care Sciences and Society Neurobiologi, vårdvetenskap och samhälle (NVS)
Division of Neurogeriatrics
141 52 HUDDINGE